Zhao, H., Ma, Y., Xue, J., Pan, Y., Tang, J., Wen, J., Li, Y., Zhang, Y., Liu, Z., Han, L., Guo, Q., Song, Z., Liao, W., Fang, Y., Zhao, X., Shi, P., Li, Z., Tian, D., Zhao, R., Zhang, L. (2026). DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3000